- Home
- PCRX vs ETD Comparison
PCRX vs ETD Comparison
Compare PCRX & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ETD
- Stock Information
- Founded
- PCRX 2006
- ETD 1932
- Country
- PCRX United States
- ETD United States
- Employees
- PCRX N/A
- ETD N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ETD Home Furnishings
- Sector
- PCRX Health Care
- ETD Consumer Discretionary
- Exchange
- PCRX Nasdaq
- ETD Nasdaq
- Market Cap
- PCRX 1.2B
- ETD 692.5M
- IPO Year
- PCRX 2011
- ETD 1993
- Fundamental
- Price
- PCRX $24.02
- ETD $28.14
- Analyst Decision
- PCRX Buy
- ETD Hold
- Analyst Count
- PCRX 9
- ETD 2
- Target Price
- PCRX $29.89
- ETD $30.00
- AVG Volume (30 Days)
- PCRX 526.9K
- ETD 248.8K
- Earning Date
- PCRX 07-29-2025
- ETD 07-30-2025
- Dividend Yield
- PCRX N/A
- ETD 7.03%
- EPS Growth
- PCRX N/A
- ETD N/A
- EPS
- PCRX N/A
- ETD 2.25
- Revenue
- PCRX $702,772,000.00
- ETD $622,924,000.00
- Revenue This Year
- PCRX $7.54
- ETD N/A
- Revenue Next Year
- PCRX $10.78
- ETD $0.96
- P/E Ratio
- PCRX N/A
- ETD $12.39
- Revenue Growth
- PCRX 3.08
- ETD N/A
- 52 Week Low
- PCRX $11.16
- ETD $24.55
- 52 Week High
- PCRX $29.33
- ETD $35.62
- Technical
- Relative Strength Index (RSI)
- PCRX 36.83
- ETD 58.94
- Support Level
- PCRX $23.85
- ETD $27.35
- Resistance Level
- PCRX $25.16
- ETD $27.93
- Average True Range (ATR)
- PCRX 0.79
- ETD 0.53
- MACD
- PCRX -0.12
- ETD 0.16
- Stochastic Oscillator
- PCRX 8.20
- ETD 100.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ETD Ethan Allen Interiors Inc.
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.